Dr Fazal-e-Rabi Subhani1*, Dr. Ahmad Ehsan Rabani2 , Dr. Fazal-i-Akbar Danish3
The In current OPV-using countries, an estimated 306-490 VAPP cases have been reported. The overall risk is about 1 case per 900,000 vaccines. This risk is exuberantly high (2 per 1000 vaccines) in individuals with B-cell immunodeficiency (OPV is thus contraindicated in immunodeficient individuals). Normal OPV recipient infants continue to shed OPV viruses for as long as 6-8 weeks after administration. In endemic places with inadequate vaccine coverage, the OPV viruses may consequently start to spread in the community.
English 
Spanish 
Chinese 
German 
French 
Japanese 
Portuguese 
Hindi